Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Clinical Diabetology
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2022

open access

Vol 12, No 1 (2023)
Guidelines / Expert consensus
Submitted: 2022-10-06
Accepted: 2022-12-08
Published online: 2022-12-27
View PDF Download PDF file
Get Citation

Approach to a Newly Diagnosed Adult with Type 2 Diabetes in the Indian Context: Recommendations by Association of Clinical Endocrinologists Consensus Group

Ravi Sankar Erukulapati1, Murali Ganguri2, Arun S. Menon3, Usha Ayyagari4, Muthu Kumar Jayapaul5, Kalyan Chakravarthy Gurazada6, Smitha Nalla7, Srinath A8, Satish Kumar Sampath9, Sudeep Putta Manohar10, Sanjay Shah11, Ravi Kumar Bachuwar12, Santhosh Olety13, Manish Kushe14, Radhika V. Kumar15, Shyam Kalavalapalli16, Mithun Bhartia17
DOI: 10.5603/DK.a2022.0061
·
CD 2023;12(1):6-37.
Affiliations
  1. Department of Endocrinology, Apollo Hospitals, Hyderabad, India
  2. Department of Endocrinology, Manipal Hospitals, Vijayawada, India
  3. Department of Endocrinology, Lisie Hospital, Kochi, Kerala, India
  4. Department of Endocrinology, Apollo Hospitals, Vanagram, Chennai, India
  5. Department of Endocrinology, Arka Center for Hormonal Health, Chennai, India
  6. Department of Endocrinology, Idea Clinics, KPHB, Hyderabad, India
  7. Department of Endocrinology, KIMS Hospital, Secunderabad, India
  8. Department of Endocrinology, BGS Gleneagles Global Hospital. Bengaluru, India
  9. Department of Endocrinology, Ameya Healthcare Multispecialty Center, HSR Layout, Bengaluru, India
  10. Department of Endocrinology, Apollo Speciality Hospital, Jayanagar, Bengaluru, India
  11. Department of Endocrinology, Narayana Super Speciality Hospital, Howrah, India
  12. Department of Endocrinology, Madhava Super Speciality Hospital, Nizamabad, Telangana, India
  13. Department of Paediatric and Adolescent Endocrine, Karnataka Institute of Endocrinology and Research, Bengaluru, India
  14. Department of Endocrinology, DiabEndocare SuperSpeciality Clinic, Goa, India
  15. Department of Endocrinology, Manipal Hospitals, Bengaluru, India
  16. Department of Endocrinology, Idea Clinics, Kukatpally, Hyderabad, India
  17. Department of Endocrinology, Bhartia Diabetic and Thyroid Clinic, Guwahati, Assam, India

open access

Vol 12, No 1 (2023)
Guidelines
Submitted: 2022-10-06
Accepted: 2022-12-08
Published online: 2022-12-27

Abstract

Not available

Abstract

Not available

Full Text:

View PDF Download PDF file
Get Citation
About this article
Title

Approach to a Newly Diagnosed Adult with Type 2 Diabetes in the Indian Context: Recommendations by Association of Clinical Endocrinologists Consensus Group

Journal

Clinical Diabetology

Issue

Vol 12, No 1 (2023)

Article type

Guidelines / Expert consensus

Pages

6-37

Published online

2022-12-27

Page views

1271

Article views/downloads

187

DOI

10.5603/DK.a2022.0061

Bibliographic record

CD 2023;12(1):6-37.

Authors

Ravi Sankar Erukulapati
Murali Ganguri
Arun S. Menon
Usha Ayyagari
Muthu Kumar Jayapaul
Kalyan Chakravarthy Gurazada
Smitha Nalla
Srinath A
Satish Kumar Sampath
Sudeep Putta Manohar
Sanjay Shah
Ravi Kumar Bachuwar
Santhosh Olety
Manish Kushe
Radhika V. Kumar
Shyam Kalavalapalli
Mithun Bhartia

References (119)
  1. International Diabetes Federation. Diabetes AtlasDIABETES ATLAS. Ninth edition. 2019. https://diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf (6.09.2022).
  2. Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021; 69(11): 2932–2938.
    CrossRefPubMed
  3. Saeedi P, Petersohn I, Salpea P, et al. IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 edition. Diabetes Res Clin Pract. 2019; 157: 107843.
    CrossRefPubMed
  4. Anjana R, Deepa M, Pradeepa R, et al. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR–INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017; 5(8): 585–596.
    CrossRefPubMed
  5. Dalkey N, Helmer O. An Experimental Application of the DELPHI Method to the Use of Experts. Management Science. 1963; 9(3): 458–467.
    CrossRef
  6. Powell C. The Delphi technique: myths and realities. J Adv Nurs. 2003; 41(4): 376–382.
    CrossRefPubMed
  7. Keeney S, Hasson F, McKenna HP. A critical review of the Delphi technique as a research methodology for nursing. Int J Nurs Stud. 2001; 38(2): 195–200.
    CrossRefPubMed
  8. Schneider P, Evaniew N, Rendon JS, et al. PARITY Investigators. Moving forward through consensus: protocol for a modified Delphi approach to determine the top research priorities in the field of orthopaedic oncology. BMJ Open. 2016; 6(5): e011780.
    CrossRefPubMed
  9. American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45(Suppl 1): S17–S38.
    CrossRefPubMed
  10. Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2021; 64(12): 2609–2652.
    CrossRefPubMed
  11. Alberti G, Zimmet P, Shaw J, et al. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care. 2004; 27(7): 1798–1811.
    CrossRefPubMed
  12. Viswanathan V, Rao V. Problems associated with diabetes care in India. Diabetes Management. 2013; 3(1): 31–40.
    CrossRef
  13. Gonzalez A, Deng Y, Lane AN, et al. Impact of mismatches in HbA vs glucose values on the diagnostic classification of diabetes and prediabetes. Diabet Med. 2020; 37(4): 689–696.
    CrossRefPubMed
  14. The Indian Council of Medical Research (ICMR) guidelines for the management of type 2 diabetes. 2018. https://main.icmr.nic.in/sites/default/files/guidelines/ICMR_GuidelinesType2diabetes2018_0.pdf (4.12.2022).
  15. Chawla R, Madhu SV, Makkar BM, et al. RSSDI-ESI Consensus Group. RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. Indian J Endocrinol Metab. 2020; 24(1): 1–122.
    CrossRefPubMed
  16. Sultanpur CM, Deepa K, Kumar SV. Comprehensive review on HbA1c in diagnosis of diabetes mellitus. Int J Pharm Sci Rev Res. 2010; 3(2): 119–122.
  17. Karnchanasorn R, Huang J, Ou HY, et al. Comparison of the Current Diagnostic Criterion of HbA1c with Fasting and 2-Hour Plasma Glucose Concentration. J Diabetes Res. 2016; 2016: 6195494.
    CrossRefPubMed
  18. Draznin B, Aroda VR, Bakris G, et al. American Diabetes Association Professional Practice Committee. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45(Suppl 1): S46–S59.
    CrossRefPubMed
  19. Butler AE, Misselbrook D. Distinguishing between type 1 and type 2 diabetes. BMJ. 2020; 370: m2998.
    CrossRefPubMed
  20. Leighton E, Sainsbury CAr, Jones GC. A Practical Review of C-Peptide Testing in Diabetes. Diabetes Ther. 2017; 8(3): 475–487.
    CrossRefPubMed
  21. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al. Type 1 Diabetes Trial Net Research Group, European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care. 2008; 31(10): 1966–1971.
    CrossRefPubMed
  22. Riddle MC, Philipson LH, Rich SS, et al. Monogenic Diabetes: From Genetic Insights to Population-Based Precision in Care. Reflections From a Editors' Expert Forum. Diabetes Care. 2020; 43(12): 3117–3128.
    CrossRefPubMed
  23. Kibirige D, Mwebaze R. Vitamin B12 deficiency among patients with diabetes mellitus: is routine screening and supplementation justified? J Diabetes Metab Disord. 2013; 12(1): 17.
    CrossRefPubMed
  24. Singla R, Garg A, Surana V, et al. Vitamin B12 Deficiency is Endemic in Indian Population: A Perspective from North India. Indian J Endocrinol Metab. 2019; 23(2): 211–214.
    CrossRefPubMed
  25. Nand L, Mahto S, Garg D, et al. Vitamin B12 deficiency in patients of type 2 diabetes mellitus treated with metformin: a cross section observational study from a tertiary care centre in Sub-Himalayan region of North India. International Journal of Research in Medical Sciences. 2020; 8(4): 1248.
    CrossRef
  26. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - . Endocr Pract. 2020; 26(1): 107–139.
    CrossRefPubMed
  27. Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2): 255–323.
    CrossRefPubMed
  28. Kanaley JA, Colberg SR, Corcoran MH, et al. Exercise/Physical Activity in Individuals with Type 2 Diabetes: A Consensus Statement from the American College of Sports Medicine. Med Sci Sports Exerc. 2022; 54(2): 353–368.
    CrossRefPubMed
  29. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018; 61(12): 2461–2498.
    CrossRefPubMed
  30. Colberg SR, Sigal RJ, Yardley JE, et al. Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care. 2016; 39(11): 2065–2079.
    CrossRefPubMed
  31. American Diabetes Association. Abridged for Primary Care Providers. Clin Diabetes. 2022; 40(1): 10–38.
    CrossRefPubMed
  32. American Diabetes Association Professional Practice Committee. 4. Lifestyle Management: Standards of Medical Care in Diabetes — 2018. Diabetes Care. 2017; 41(Suppl. 1): S38–S50.
    CrossRef
  33. Evert AB, Boucher JL, Cypress M, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care. 2014; 37(Suppl. 1): S120–S143.
    CrossRefPubMed
  34. Sadeghi F, Salehi S, Kohanmoo A, et al. Effect of natural honey on glycemic control and anthropometric measures of patients with type 2 diabetes: a randomized controlled crossover trial. Int J Prev Med. 2019; 10: 3.
    CrossRefPubMed
  35. Bahrami M, Ataie-Jafari A, Hosseini S, et al. Effects of natural honey consumption in diabetic patients: an 8-week randomized clinical trial. Int J Food Sci Nutr. 2009; 60(7): 618–626.
    CrossRefPubMed
  36. Evert AB, Dennison M, Gardner CD, et al. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care. 2019; 42(5): 731–754.
    CrossRefPubMed
  37. American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes - 2022. Diabetes Care. 2022; 45(Suppl 1): S113–S124.
    CrossRefPubMed
  38. Mathews E, Thomas E, Absetz P, et al. Cultural adaptation of a peer-led lifestyle intervention program for diabetes prevention in India: the Kerala diabetes prevention program (K-DPP). BMC Public Health. 2018; 17(1): 974.
    CrossRefPubMed
  39. Weber MB, Ranjani H, Staimez LR, et al. The stepwise approach to diabetes prevention: results from the D-CLIP randomized controlled trial. Diabetes Care. 2016; 39(10): 1760–1767.
    CrossRefPubMed
  40. Gulati S, Misra A, Tiwari R, et al. Effect of high-protein meal replacement on weight and cardiometabolic profile in overweight/obese Asian Indians in North India. Br J Nutr. 2017; 117(11): 1531–1540.
    CrossRefPubMed
  41. Malik VS, Sudha V, Wedick NM, et al. Substituting brown rice for white rice on diabetes risk factors in India: a randomised controlled trial. Br J Nutr. 2019; 121(12): 1389–1397.
    CrossRefPubMed
  42. American Diabetes Association Professional Practice Committee. 6. Glycemic Targets: Standards of Medical Care in Diabetes - 2022. Diabetes Care. 2022; 45(Suppl 1): S83–S96.
    CrossRefPubMed
  43. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015; 58(3): 429–442.
    CrossRefPubMed
  44. Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24): 2545–2559.
    CrossRefPubMed
  45. Kalra S, Shaikh S, Priya G, et al. Individualizing Time-in-Range Goals in Management of Diabetes Mellitus and Role of Insulin: Clinical Insights From a Multinational Panel. Diabetes Ther. 2021; 12(2): 465–485.
    CrossRefPubMed
  46. American Diabetes Association Professional Practice Committee. 13. Older Adults: Standards of Medical Care in Diabetes - 2022. Diabetes Care. 2022; 45(Suppl 1): S195–S207.
    CrossRefPubMed
  47. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013; 36(5): 1384–1395.
    CrossRefPubMed
  48. Davis HA, Spanakis EK, Cryer PE, et al. Hypoglycemia During Therapy of Diabetes. Endotext [Internet]. 2015.
    PubMed
  49. NHS. The Hospital Management of Hypoglycaemia in Adults with Diabetes Mellitus. 2010. http://www.diabetologists-abcd.org.uk/jbds/JBDS_IP_Hypo_Adults.pdf (4.12.2022).
  50. Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetologia. 2021; 64(11): 2359–2366.
    CrossRefPubMed
  51. Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetologia. 2021; 44(10): 2438–2444.
    CrossRefPubMed
  52. Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009; 32(11): 2133–2135.
    CrossRefPubMed
  53. Brown E, Wilding JPH, Barber TM, et al. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. Obes Rev. 2019; 20(6): 816–828.
    CrossRefPubMed
  54. Narayan KMV, Boyle JP, Thompson TJ, et al. Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care. 2007; 30(6): 1562–1566.
    CrossRefPubMed
  55. Misra A, Chowbey P, Makkar BM, et al. Concensus Group. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India. 2009; 57: 163–170.
    PubMed
  56. Aziz N, Kallur SD, Nirmalan PK. Implications of the revised consensus body mass indices for asian indians on clinical obstetric practice. J Clin Diagn Res. 2014; 8(5): OC01–OC03.
    CrossRefPubMed
  57. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998; 21(8): 1288–1294.
    CrossRefPubMed
  58. Jacob S, Rabbia M, Meier MK, et al. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009; 11(4): 361–371.
    CrossRefPubMed
  59. NICE Guidelines. 2015. Type 2 diabetes in adults: management. https://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-management-pdf-1837338615493 (4.12.2022).
  60. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45(Suppl 1): S125–S143.
    CrossRefPubMed
  61. Apovian CM, Okemah J, O'Neil PM. Body Weight Considerations in the Management of Type 2 Diabetes. Adv Ther. 2019; 36(1): 44–58.
    CrossRefPubMed
  62. Schroeder EBN. Management of Type 2 Diabetes: Selecting Amongst Available Pharmacological Agents. Endotext [Internet]. 2022.
  63. Lipscombe L, Booth G, Butalia S, et al. Diabetes Canada Clinical Practice Guidelines Expert Committee. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. Can J Diabetes. 2018; 42(Suppl 1): S88–S8S103.
    CrossRefPubMed
  64. Silver B, Ramaiya K, Andrew SB, et al. EADSG guidelines: insulin therapy in diabetes. Diabetes Ther. 2018; 9(2): 449–492.
    CrossRefPubMed
  65. American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes - 2022. Diabetes Care. 2022; 45(Suppl 1): S144–S174.
    CrossRefPubMed
  66. de Boer IH, Bangalore S, Benetos A, et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(9): 1273–1284.
    CrossRefPubMed
  67. Koopman RJ, Wakefield BJ, Johanning JL, et al. Implementing home blood glucose and blood pressure telemonitoring in primary care practices for patients with diabetes: lessons learned. Telemed J E Health. 2014; 20(3): 253–260.
    CrossRefPubMed
  68. Omboni S, Gazzola T, Carabelli G, et al. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens. 2013; 31(3): 455–467; discussion 467-468.
    CrossRefPubMed
  69. Tsai SY, Huang WH, Chan HL, et al. The role of smoking cessation programs in lowering blood pressure: a retrospective cohort study. Tob Induc Dis. 2021; 19: 82.
    CrossRefPubMed
  70. Solano M, Goldberg R. Lipid Management in Type 2 Diabetes. Clin Diabetes. 2006; 24(1): 27–32.
    CrossRef
  71. Farukhi Z, Mora S. Re-assessing the role of non-fasting lipids; a change in perspective. Ann Transl Med. 2016; 4(21): 431.
    CrossRefPubMed
  72. Parhofer KG, Laufs U. The Diagnosis and Treatment of Hypertriglyceridemia. Dtsch Arztebl Int. 2019; 116(49): 825–832.
    CrossRefPubMed
  73. Kearney PM, Blackwell L, Collins R, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008; 371(9607): 117–125.
    CrossRefPubMed
  74. Jani RH, Pai V, Jha P, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther. 2014; 16(2): 63–71.
    CrossRefPubMed
  75. Chandra KS, Bansal M, Nair T, et al. Consensus statement on management of dyslipidemia in Indian subjects. Indian Heart J. 2014; 66 Suppl 3(Suppl 3): S1–51.
    CrossRefPubMed
  76. Bowman L, Mafham M, Wallendszus K, et al. ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018; 379(16): 1529–1539.
    CrossRefPubMed
  77. De Berardis G, Sacco M, Strippoli GFM, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009; 339: b4531.
    CrossRefPubMed
  78. Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373(9678): 1849–1860.
    CrossRefPubMed
  79. Ittaman SV, VanWormer JJ, Rezkalla SH. The role of aspirin in the prevention of cardiovascular disease. Clin Med Res. 2014; 12(3-4): 147–154.
    CrossRefPubMed
  80. Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007; 297(18): 2018–2024.
    CrossRefPubMed
  81. Grant PJ, Cosentino F. The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: New features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosentino, the Task Force chairmen. Eur Heart J. 2019; 40(39): 3215–3217.
    CrossRefPubMed
  82. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117–2128.
    CrossRefPubMed
  83. Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020; 63(2): 221–228.
    CrossRefPubMed
  84. Zhang Y, Ding X, Hua B, et al. Real-world use of ACEI/ARB in diabetic hypertensive patients before the initial diagnosis of obstructive coronary artery disease: patient characteristics and long-term follow-up outcome. J Transl Med. 2020; 18: 150.
    CrossRefPubMed
  85. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011; 34(6): 1431–1437.
    CrossRefPubMed
  86. American Diabetes Association Professional Practice Committee. Addendum 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45(Suppl 1): 2182–2184.
    CrossRefPubMed
  87. Bandak G, Sang Y, Gasparini A, et al. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc. 2017; 6(7).
    CrossRefPubMed
  88. Kidney International supplements. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf (4.12.2022).
  89. Smart NA, Dieberg G, Ladhani M, et al. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane Database Syst Rev. 2014(6): CD007333.
    CrossRefPubMed
  90. American Diabetes Association Professional Practice Committee. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes - 2022. Diabetes Care. 2022; 45(Suppl 1): S185–S194.
    CrossRefPubMed
  91. Solomon SD, Chew E, Duh EJ, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(3): 412–418.
    CrossRefPubMed
  92. Bragge P, Gruen RL, Chau M, et al. Screening for presence or absence of diabetic retinopathy: a meta-analysis. Arch Ophthalmol. 2011; 129(4): 435–444.
    CrossRefPubMed
  93. Raman R, Ramasamy K, Rajalakshmi S, et al. Diabetic retinopathy screening guidelines in India: All India Ophthalmological Society diabetic retinopathy task force and Vitreoretinal Society of India Consensus Statement. Indian J Ophthalmol. 2021; 69(3): 678–688.
    CrossRefPubMed
  94. Bril V, Breiner A, Perkins B, et al. Diabetes Canada Clinical Practice Guidelines Expert Committee. Neuropathy. Can J Diabetes. 2018; 42(Suppl 1): S217–S221.
    CrossRefPubMed
  95. Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(1): 136–154.
    CrossRefPubMed
  96. Tan LS. The clinical use of the 10g monofilament and its limitations: a review. Diabetes Res Clin Pract. 2010; 90(1): 1–7.
    CrossRefPubMed
  97. Yang H, Sloan G, Ye Y, et al. New Perspective in Diabetic Neuropathy: From the Periphery to the Brain, a Call for Early Detection, and Precision Medicine. Front Endocrinol (Lausanne). 2019; 10: 929.
    CrossRefPubMed
  98. Boulton AJM, Armstrong DG, Albert SF, et al. Comprehensive foot examination and risk assessment. A report of the Task Force of the Foot Care Interest Group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care. 2008; 31(8): 1879–1685.
    CrossRefPubMed
  99. Lipsky BA, Berendt AR, Cornia PB, et al. Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012; 54(12): e132–e173.
    CrossRefPubMed
  100. Hingorani A, LaMuraglia GM, Henke P, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016; 63(2 Suppl): 3S–321S.
    CrossRefPubMed
  101. Sharma B, John S. Nonalcoholic Steatohepatitis (NASH). StatPearls [Internet]. 2022.
  102. Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic Steatohepatitis: A Review. JAMA. 2020; 323(12): 1175–1183.
    CrossRefPubMed
  103. Targher G, Corey KE, Byrne CD, et al. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021; 18(9): 599–612.
    CrossRefPubMed
  104. Kim KS, Lee BW. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. Clin Mol Hepatol. 2020; 26(4): 430–443.
    CrossRefPubMed
  105. Gawrieh S, Noureddin M, Loo N, et al. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021; 74(4): 1809–1824.
    CrossRefPubMed
  106. Hashem A, Khalouf A, Acosta A. Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review. Semin Liver Dis. 2021; 41(4): 435–447.
    CrossRefPubMed
  107. Kesavadev J, Misra A, Das AK, et al. Suggested use of vaccines in diabetes. Indian J Endocrinol Metab. 2012; 16(6): 886–893.
    CrossRefPubMed
  108. American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45(Suppl 1): S232–S243.
    CrossRefPubMed
  109. Bullo M, Tschumi S, Bucher BS, et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension. 2012; 60(2): 444–450.
    CrossRefPubMed
  110. Bomba-Opoń D, Hirnle L, Kalinka J, et al. Folate supplementation during the preconception period, pregnancy and puerperium. Polish Society of Gynecologists and Obstetricians Guidelines. Ginekol Pol. 2017; 88(11): 633–636.
    CrossRefPubMed
  111. Parker SE, Yazdy MM, Tinker SC, et al. The impact of folic acid intake on the association among diabetes mellitus, obesity, and spina bifida. Am J Obstet Gynecol. 2013; 209(3): 239.e1–239.e8.
    CrossRefPubMed
  112. American Diabetes Association Professional Practice Committee. 16. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes - 2022. Diabetes Care. 2022; 45(Suppl 1): S244–S253.
    CrossRefPubMed
  113. Umpierrez GE, Reyes D, Smiley D, et al. Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes. Diabetes Care. 2014; 37(11): 2934–2939.
    CrossRefPubMed
  114. Pasquel FJ, Gomez-Huelgas R, Anzola I, et al. Predictive Value of Admission Hemoglobin A1c on Inpatient Glycemic Control and Response to Insulin Therapy in Medicine and Surgery Patients With Type 2 Diabetes. Diabetes Care. 2015; 38(12): e202–e203.
    CrossRefPubMed
  115. Maynard G, Wesorick DH, O'Malley C, et al. Society of Hospital Medicine Glycemic Control Task Force. Subcutaneous insulin order sets and protocols: effective design and implementation strategies. J Hosp Med. 2008; 3(5 Suppl): 29–41.
    CrossRefPubMed
  116. American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Medical Care in Diabetes - 2022. Diabetes Care. 2022; 45(Suppl 1): S97–S112.
    CrossRefPubMed
  117. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019; 42(8): 1593–1603.
    CrossRefPubMed
  118. Reddy N, Verma N, Dungan K. Monitoring Technologies- Continuous Glucose Monitoring, Mobile Technology, Biomarkers of Glycemic Control. Endotext [Internet]. 2020.
  119. Reznik Y, Cohen O. Insulin pump for type 2 diabetes: use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes. Diabetes Care. 2013; 36 Suppl 2(Suppl 2): S219–S225.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl